Aristea Velegraki - Concepedia

Author

Aristea Velegraki

National and Kapodistrian University of Athens ORCID

Also Known As

A VELEGRAKI, A Velegraki, A. VELEGRAKI, A. Velegraki, Aristea Velegraki, Mayser, Peter, Velegraki A.

208

Publications

8.2K

Citations

H-Index

128

Concepts

All Affiliations

National and Kapodistrian University of Athens University of Ioannina Aristotle University of Thessaloniki University of Milan Westmead Hospital

About

Aristea Velegraki is an author at National and Kapodistrian University of Athens specializing in medicine, microbiology, and clinical microbiology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	32	58	3.7K
2	Engineering	9	9	261
3	Health Sciences	7	7	316
4	Natural Sciences	2	2	95
5	Public Health	1	1	23

Aristea Velegraki

Publications

5.6K

Citations

H-Index

Page 1

	Year	Citations
EUCAST Definitive Document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts J. L. Rodríguez-Tudela, Maiken Cavling Arendrup, Francesco Barchiesi, Clinical Microbiology and Infection Antifungal AgentDilution MicsAntifungal AgentsBioanalysisYeast	2008	644
International Society of Human and Animal Mycology (ISHAM)-ITS reference DNA barcoding database—the quality controlled standard tool for routine identification of human and animal pathogenic fungi László Irinyi, Carolina Serena, Dea Garcia‐Hermoso, Medical Mycology Diagnostic MycologyPathologyReference DnaClinical MycologyGenomics	2015	315
Results From a Prospective, International, Epidemiologic Study of Invasive Candidiasis in Children and Neonates William J. Steinbach, Emmanuel Roilides, David M. Berman, The Pediatric Infectious Disease Journal	2012	176
Malassezia Yeasts Produce a Collection of Exceptionally Potent Activators of the Ah (Dioxin) Receptor Detected in Diseased Human Skin Prokopios Magiatis, Periklis Pappas, Nikitia Mexia, Journal of Investigative Dermatology Antifungal AgentFungal Cell BiologyMedicineDiseased Human SkinExceptionally Potent Activators	2013	160
Candidal overgrowth in diabetic patients: potential predisposing factors Maria Belazi, Aristea Velegraki, Alexandra Fleva, Mycoses Fungal PathogenCandidal OvergrowthOral CavityDiabetesPathology	2005	148
Autochthonous and Dormant<i>Cryptococcus gattii</i>Infections in Europe Ferry Hagen, María Francisca Colom, D. Swinne, Emerging infectious diseases Human Patient IsolatesPathogenic MicrobiologyMicrobial DiseaseMedicinePathogenesis	2012	142
Environmental distribution of<i>Cryptococcus neoformans</i>and<i>C. gattii</i>around the Mediterranean basin Massimo Cogliati, Roberta D’Amicis, Alberto Zani, FEMS Yeast Research BiologyMediterranean EnvironmentMicrobial DiversityEnvironmental DistributionMicrobial Systematics	2016	139
Molecular analysis of 311<i>Cryptococcus neoformans</i>isolates from a 30-month ECMM survey of cryptococcosis in Europe Maria Anna Viviani, Massimo Cogliati, Maria Carmela Esposto, FEMS Yeast Research Diagnostic MycologyEuropean ConfederationMolecular AnalysisPathologyCryptococcus Neoformans	2006	136
Invasive Candida infections in surgical patients in intensive care units: a prospective, multicentre survey initiated by the European Confederation of Medical Mycology (ECMM) (2006–2008) Lena Klingspor, Anna Maria Tortorano, Javier Pemán, Clinical Microbiology and Infection European ConfederationAntifungal AgentsInvasive Candida InfectionsHealthcare-associated InfectionClinical Epidemiology	2014	134
Soluble Urokinase Plasminogen Activator Receptor Level Is an Independent Predictor of the Presence and Severity of Coronary Artery Disease and of Future Adverse Events Danny J. Eapen, Pankaj Manocha, Nima Ghasemzadeh, Journal of the American Heart Association	2014	133

Page 1